Arthritis medicines and cardiovascular events - "House of coxibs"

[1] Selective COX-2 inhibition improves endothelial function in coronary artery disease [J]. CIRCULATION, 2003, 107 (03) : 405 - 409

[2] Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (11) : 1243 - 1246

[3] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J]. LANCET, 2004, 364 (9435) : 675 - 684

[4] Postmarketing surveillance - Lack of vigilance, lack of trust [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21): : 2647 - 2650

[5] GRAHAM DJ, 2004, PHARMACOEPIDEM DR S, V13, pS287

[6] Harris Gardiner, 2004, N Y Times Web, pA19

[7] Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries [J]. CIRCULATION, 2001, 104 (07) : 820 - 825

[8] Risk of cardiovascular events and rofecoxib: cumulative meta-analysis [J]. LANCET, 2004, 364 (9450) : 2021 - 2029

[9] KIMMEL SE, 2004, ANN INTERN MED 1207

[10] Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study [J]. LANCET, 2004, 363 (9423) : 1751 - 1756

[1] Selective COX-2 inhibition improves endothelial function in coronary artery disease [J]. CIRCULATION, 2003, 107 (03) : 405 - 409

[2] Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (11) : 1243 - 1246

[3] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J]. LANCET, 2004, 364 (9435) : 675 - 684

[4] Postmarketing surveillance - Lack of vigilance, lack of trust [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (21): : 2647 - 2650

[5] GRAHAM DJ, 2004, PHARMACOEPIDEM DR S, V13, pS287

[6] Harris Gardiner, 2004, N Y Times Web, pA19

[7] Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries [J]. CIRCULATION, 2001, 104 (07) : 820 - 825

[8] Risk of cardiovascular events and rofecoxib: cumulative meta-analysis [J]. LANCET, 2004, 364 (9450) : 2021 - 2029

[9] KIMMEL SE, 2004, ANN INTERN MED 1207

[10] Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study [J]. LANCET, 2004, 363 (9423) : 1751 - 1756